132 related articles for article (PubMed ID: 10319212)
1. Evaluation of costs in rheumatic diseases: a literature review.
Ruof J; Hülsemann JL; Stucki G
Curr Opin Rheumatol; 1999 Mar; 11(2):104-9. PubMed ID: 10319212
[TBL] [Abstract][Full Text] [Related]
2. Socioeconomic evaluation of rheumatoid arthritis and osteoarthritis: a literature review.
Rothfuss J; Mau W; Zeidler H; Brenner MH
Semin Arthritis Rheum; 1997 Apr; 26(5):771-9. PubMed ID: 9144852
[TBL] [Abstract][Full Text] [Related]
3. A Systematic Review of the Incidence, Prevalence, Costs, and Activity and Work Limitations of Amputation, Osteoarthritis, Rheumatoid Arthritis, Back Pain, Multiple Sclerosis, Spinal Cord Injury, Stroke, and Traumatic Brain Injury in the United States: A 2019 Update.
Lo J; Chan L; Flynn S
Arch Phys Med Rehabil; 2021 Jan; 102(1):115-131. PubMed ID: 32339483
[TBL] [Abstract][Full Text] [Related]
4. Incidence, prevalence, costs, and impact on disability of common conditions requiring rehabilitation in the United States: stroke, spinal cord injury, traumatic brain injury, multiple sclerosis, osteoarthritis, rheumatoid arthritis, limb loss, and back pain.
Ma VY; Chan L; Carruthers KJ
Arch Phys Med Rehabil; 2014 May; 95(5):986-995.e1. PubMed ID: 24462839
[TBL] [Abstract][Full Text] [Related]
5. Costs of pain in rheumatology.
Marsico A; Atzeni F; Piroddi A; Cazzola M; Stisi S; Sarzi-Puttini P
Reumatismo; 2014 Jun; 66(1):103-7. PubMed ID: 24938203
[TBL] [Abstract][Full Text] [Related]
6. The need for standardization: a literature review of indirect costs of rheumatoid arthritis and osteoarthritis.
Xie F
Arthritis Rheum; 2008 Jul; 59(7):1027-33. PubMed ID: 18576305
[No Abstract] [Full Text] [Related]
7. Development of a matrix of cost domains in economic evaluation of rheumatoid arthritis.
Merkesdal S; Ruof J; Huelsemann JL; Schoeffski O; Maetzel A; Mau W; Zeidler H
J Rheumatol; 2001 Mar; 28(3):657-61. PubMed ID: 11296977
[TBL] [Abstract][Full Text] [Related]
8. Assessing cost-effectiveness analyses in rheumatoid arthritis and osteoarthritis.
Ruchlin HS; Elkin EB; Paget SA
Arthritis Care Res; 1997 Dec; 10(6):413-21. PubMed ID: 9481233
[TBL] [Abstract][Full Text] [Related]
9. Women and arthritis: burden, impact and prevention programs.
Hootman JM; Sniezek JE; Helmick CG
J Womens Health Gend Based Med; 2002 Jun; 11(5):407-16. PubMed ID: 12173574
[TBL] [Abstract][Full Text] [Related]
10. The burden of rheumatoid arthritis: facts and figures.
Callahan LF
J Rheumatol Suppl; 1998 Jul; 53():8-12. PubMed ID: 9666412
[TBL] [Abstract][Full Text] [Related]
11. Economic outcomes for celecoxib: a systematic review of pharmacoeconomic studies.
Huelin R; Pokora T; Foster TS; Mould JF
Expert Rev Pharmacoecon Outcomes Res; 2012 Aug; 12(4):505-23. PubMed ID: 22971036
[TBL] [Abstract][Full Text] [Related]
12. Resource utilization and cost of care for rheumatoid arthritis and osteoarthritis in a managed care setting: the importance of drug and surgery costs.
Lanes SF; Lanza LL; Radensky PW; Yood RA; Meenan RF; Walker AM; Dreyer NA
Arthritis Rheum; 1997 Aug; 40(8):1475-81. PubMed ID: 9259428
[TBL] [Abstract][Full Text] [Related]
13. Economic evaluation of etoricoxib versus non-selective NSAIDs in the treatment of osteoarthritis and rheumatoid arthritis patients in the UK.
Moore A; Phillips C; Hunsche E; Pellissier J; Crespi S
Pharmacoeconomics; 2004; 22(10):643-60. PubMed ID: 15244490
[TBL] [Abstract][Full Text] [Related]
14. Arthritis treatment in Hong Kong--cost analysis of celecoxib versus conventional NSAIDS, with or without gastroprotective agents.
You JH; Lee KK; Chan TY; Lau WH; Chan FK
Aliment Pharmacol Ther; 2002 Dec; 16(12):2089-96. PubMed ID: 12452942
[TBL] [Abstract][Full Text] [Related]
15. Infliximab: a pharmacoeconomic review of its use in rheumatoid arthritis.
Lyseng-Williamson KA; Foster RH
Pharmacoeconomics; 2004; 22(2):107-32. PubMed ID: 14731052
[TBL] [Abstract][Full Text] [Related]
16. The economic burden associated with osteoarthritis, rheumatoid arthritis, and hypertension: a comparative study.
Maetzel A; Li LC; Pencharz J; Tomlinson G; Bombardier C;
Ann Rheum Dis; 2004 Apr; 63(4):395-401. PubMed ID: 15020333
[TBL] [Abstract][Full Text] [Related]
17. Direct medical costs unique to people with arthritis.
Gabriel SE; Crowson CS; Campion ME; O'Fallon WM
J Rheumatol; 1997 Apr; 24(4):719-25. PubMed ID: 9101508
[TBL] [Abstract][Full Text] [Related]
18. The Swedish ACCES model: predicting the health economic impact of celecoxib in patients with osteoarthritis or rheumatoid arthritis.
Haglund U; Svarvar P
Rheumatology (Oxford); 2000 Dec; 39 Suppl 2():51-6. PubMed ID: 11276803
[TBL] [Abstract][Full Text] [Related]
19. Costs, outcomes, and patient satisfaction by provider type for patients with rheumatic and musculoskeletal conditions: a critical review of the literature and proposed methodologic standards.
Solomon DH; Bates DW; Panush RS; Katz JN
Ann Intern Med; 1997 Jul; 127(1):52-60. PubMed ID: 9214253
[TBL] [Abstract][Full Text] [Related]
20. Estimating the health-care usage associated with osteoarthritis and rheumatoid arthritis in an older adult population in Ireland.
Doherty E; O'Neill C
J Public Health (Oxf); 2014 Sep; 36(3):504-10. PubMed ID: 24097191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
